Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate 4D Molecular Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding 4D Molecular Therapeutics, Inc.’s stock price such as:

• 4D Molecular Therapeutics, Inc.’s current stock price and volume
• Why 4D Molecular Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for FDMT from analysts
• FDMT’s stock price momentum as measured by its relative strength

About 4D Molecular Therapeutics, Inc. (FDMT)

Before we jump into 4D Molecular Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company’s lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.

Want to learn more about 4D Molecular Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about 4D Molecular Therapeutics, Inc..

4D Molecular Therapeutics, Inc.’s Stock Price as of Market Close

As of April 16, 2026, 3:31 PM, CST, 4D Molecular Therapeutics, Inc.’s stock price was $9.690.

4D Molecular Therapeutics, Inc. is down 0.82% from its previous closing price of $9.770.

During the last market session, 4D Molecular Therapeutics, Inc.’s stock traded between $9.530 and $9.860. Currently, there are approximately 63.92 million shares outstanding for 4D Molecular Therapeutics, Inc..

4D Molecular Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

4D Molecular Therapeutics, Inc. Stock Price History

4D Molecular Therapeutics, Inc.’s (FDMT) price is currently up 4.08% so far this month.

During the month of April, 4D Molecular Therapeutics, Inc.’s stock price has reached a high of $10.880 and a low of $9.375.

Over the last year, 4D Molecular Therapeutics, Inc. has hit prices as high as $12.340 and as low as $2.880. Year to date, 4D Molecular Therapeutics, Inc.’s stock is up 29.2%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused 4D Molecular Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 15, 2026, there were 0 analysts who downgraded 4D Molecular Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate 4D Molecular Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on 4D Molecular Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

4D Molecular Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about 4D Molecular Therapeutics, Inc. (FDMT) by visiting AAII Stock Evaluator.

Relative Price Strength of 4D Molecular Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 15, 2026, 4D Molecular Therapeutics, Inc. has a weighted four-quarter relative price strength of 31.44%, which translates to a Momentum Score of 94 and is considered to be Very Strong.

Want to learn more about how 4D Molecular Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

4D Molecular Therapeutics, Inc. Stock Price: Bottom Line

As of April 16, 2026, 4D Molecular Therapeutics, Inc.’s stock price is $9.690, which is down 0.82% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like 4D Molecular Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.